CO6290633A2 - Sistema de administracion de drogas que contieen estra-diol - Google Patents

Sistema de administracion de drogas que contieen estra-diol

Info

Publication number
CO6290633A2
CO6290633A2 CO10100017A CO10100017A CO6290633A2 CO 6290633 A2 CO6290633 A2 CO 6290633A2 CO 10100017 A CO10100017 A CO 10100017A CO 10100017 A CO10100017 A CO 10100017A CO 6290633 A2 CO6290633 A2 CO 6290633A2
Authority
CO
Colombia
Prior art keywords
diol
drug administration
system containing
administration system
wafers
Prior art date
Application number
CO10100017A
Other languages
English (en)
Inventor
Adrian Funke
Sascha General
Ildiko Terebesi
Christian Zurth
Sofia Alincic-Kunz
Matthias Schaefer
Thomas Holler
Konstanze Diefenbach
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39365963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6290633(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CO6290633A2 publication Critical patent/CO6290633A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Abstract

La presente invención se refiere a sistemas de administración de drogas en la forma de películas delgadas solubles en agua (obleas), que contienen estradiol, o derivados del mismo, en cantidades bajas. Las obleas de la presente invención son adecuadas para tratar, aliviar o prevenir una condición física en un mamífero hembra causada por niveles endógenos de estrógeno insuficientes.
CO10100017A 2008-02-13 2010-08-13 Sistema de administracion de drogas que contieen estra-diol CO6290633A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2830208P 2008-02-13 2008-02-13
EP08002633 2008-02-13

Publications (1)

Publication Number Publication Date
CO6290633A2 true CO6290633A2 (es) 2011-06-20

Family

ID=39365963

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10100017A CO6290633A2 (es) 2008-02-13 2010-08-13 Sistema de administracion de drogas que contieen estra-diol

Country Status (27)

Country Link
US (1) US20110097405A1 (es)
EP (1) EP2249803A2 (es)
JP (1) JP2011511823A (es)
KR (1) KR20100125309A (es)
CN (1) CN101945646A (es)
AR (1) AR070375A1 (es)
AU (1) AU2009214193A1 (es)
BR (1) BRPI0908477A2 (es)
CA (1) CA2714340A1 (es)
CL (1) CL2009000326A1 (es)
CO (1) CO6290633A2 (es)
CR (1) CR11632A (es)
DO (1) DOP2010000252A (es)
EA (1) EA201001245A1 (es)
EC (1) ECSP10010400A (es)
IL (1) IL206640A0 (es)
MA (1) MA32073B1 (es)
MX (1) MX2010008940A (es)
NZ (1) NZ586666A (es)
PA (1) PA8816001A1 (es)
PE (1) PE20091471A1 (es)
TN (1) TN2010000302A1 (es)
TW (1) TW200940095A (es)
UA (1) UA102680C2 (es)
UY (1) UY31660A1 (es)
WO (1) WO2009101021A2 (es)
ZA (1) ZA201006517B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
GB201200062D0 (en) 2012-01-04 2012-02-15 Innotesto Bvba Estradiol oromucosal liquid compositions
WO2014018075A1 (en) 2012-07-23 2014-01-30 Crayola, Llc Dissolvable films and methods of using the same
CA2978305A1 (en) * 2015-03-02 2016-09-09 Colonaryconcepts Llc Compounds and methods for peg metabolite and peg breakdown product assays

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136162A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
JPS56140915A (en) * 1980-04-07 1981-11-04 Yamanouchi Pharmaceut Co Ltd Pharmaceutical preparation for solid drug
DE3347125A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
WO1993023011A1 (en) * 1992-05-18 1993-11-25 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device
DE4426709A1 (de) * 1994-07-20 1996-01-25 Schering Ag Steroidale Sexualhormone enthaltende feste Arzneiformen
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
AU3567699A (en) * 1998-04-17 1999-11-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
CH693905A5 (de) * 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20030092658A1 (en) * 2001-02-02 2003-05-15 Meyers Rachel E. Novel human enzyme family members and uses thereof
AU2001258341B2 (en) * 2000-04-12 2007-03-15 Schering Aktiengesellschaft 8beta-hydrocarbyl-substituted estratrienes for use as selective estrogens
EP1216712A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
AU2002309919B2 (en) * 2001-05-16 2008-04-10 Barr Laboratories, Inc. Treatment of conditions relating to hormone deficiencies by administration of progestins
EP1413294B1 (en) * 2001-07-27 2010-09-29 Astellas Pharma Inc. Composition comprising sustained-release fine particles for quick-disintegrating tablets in the buccal cavity
DE10207394B4 (de) * 2002-02-21 2007-03-29 Lts Lohmann Therapie-Systeme Ag Geschmacksmaskierte oblatenförmige Arzneizubereitung
EA007599B1 (ru) * 2002-02-21 2006-12-29 Шеринг Акциенгезельшафт Фармацевтические композиции, содержащие один или несколько стероидов, один или несколько тетрагидрофолатных компонентов и витамин в
WO2005004989A2 (en) * 2003-07-01 2005-01-20 Todd Maibach Film comprising therapeutic agents
CN1913876B (zh) * 2003-12-09 2013-06-26 大日本住友制药株式会社 含药物的颗粒和包含这种颗粒的固体制剂
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
US20050220825A1 (en) * 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
DE102004023984A1 (de) * 2004-05-14 2005-12-08 Hf Arzneimittelforschung Gmbh Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
DE102005015128B4 (de) * 2005-03-31 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Wafer enthaltend Steroidhormone
WO2006127879A1 (en) * 2005-05-26 2006-11-30 Duramed Pharmaceuticals, Inc. Flexible solid dosage forms and methods of making and using the same
DE102005058569B4 (de) * 2005-12-08 2010-07-15 Lts Lohmann Therapie-Systeme Ag Schaumwafer mit Polyvinylalkohol-Polyethylenglycol-Pfropfcopolymer
DE102005062270A1 (de) * 2005-12-24 2007-06-28 Bayer Technology Services Gmbh Geschmacksmaskierung von Pulvern
DE102006003512A1 (de) * 2006-01-24 2007-08-02 Bayer Schering Pharma Ag Plättchenförmige Arzneimittel zur transbukkalen Applikation von Arzneistoffen
EP1867321A3 (en) * 2006-06-07 2008-11-19 Familplan Consulting Ltd. A pharmaceutical product adapted for oral transmucosal administration comprising a pharmaceutical agent
DE102006027792A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antidepressiva-Kombinations-Wafer
DE102006027796A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Estrogen-Gestagen-Kombinationen
US20080058272A1 (en) * 2006-08-29 2008-03-06 Juergen Becker Nonamer Peptides for Cancer Treatment

Also Published As

Publication number Publication date
CR11632A (es) 2010-10-05
TW200940095A (en) 2009-10-01
NZ586666A (en) 2012-04-27
CA2714340A1 (en) 2009-08-20
MA32073B1 (fr) 2011-02-01
WO2009101021A2 (en) 2009-08-20
IL206640A0 (en) 2010-12-30
ZA201006517B (en) 2014-02-26
CN101945646A (zh) 2011-01-12
US20110097405A1 (en) 2011-04-28
TN2010000302A1 (en) 2011-11-11
DOP2010000252A (es) 2010-08-31
UY31660A1 (es) 2009-09-30
MX2010008940A (es) 2010-10-05
EP2249803A2 (en) 2010-11-17
EA201001245A1 (ru) 2011-04-29
BRPI0908477A2 (pt) 2018-03-27
ECSP10010400A (es) 2010-09-30
AR070375A1 (es) 2010-03-31
AU2009214193A1 (en) 2009-08-20
CL2009000326A1 (es) 2010-07-19
WO2009101021A3 (en) 2009-12-30
UA102680C2 (ru) 2013-08-12
PE20091471A1 (es) 2009-10-25
KR20100125309A (ko) 2010-11-30
PA8816001A1 (es) 2009-09-17
JP2011511823A (ja) 2011-04-14

Similar Documents

Publication Publication Date Title
CR20120493A (es) Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis
CR20110072A (es) Sistema de administración de drogas que contiene progestina
BR112016000194A8 (pt) forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
BR112016012615A8 (pt) sistemas, e kit
UY30056A1 (es) Administracion transdermica de meptazinol
PE20071244A1 (es) Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas)
GT201000144A (es) " composiciones farmaceuticas "
MX367868B (es) Composiciones antimicrobianas.
BR112012027404A2 (pt) dispositivo de entrega de droga em camadas
PE20091574A1 (es) Sistema de administracion de drogas con efecto estabilizante
CO6290633A2 (es) Sistema de administracion de drogas que contieen estra-diol
BR112014010509A2 (pt) sistema de dispensa vaginal osmoticamente ativo
WO2013095286A3 (en) Synergistic combination comprising avermectins and a nsaid for tumor inhibition
CO6650363A2 (es) Preparación recubierta con partículas finas
ECSP10010505A (es) Composición farmacéutica
ECSP13012977A (es) Composiciones y métodos para separar, caracterizar y administrar selenoglicoproteínas solubles
CU20100164A7 (es) Sistemas de administración de drogas que contienen estradiol
CO6771460A2 (es) Tratamiento de la atrofia vaginal con nueva indicación para la mirra
WO2016014680A8 (en) Oral transmucosal compositions including aromatase inhibitors for low testosterone levels in men
CO6331424A2 (es) Formulacion farmaceutica de eprosartan
TH105098A (th) ระบบนำส่งยาที่ประกอบด้วยเอสทราไดออล
WO2016028903A8 (en) Oral transmucosal pharmaceutical compositions including testosterone and a c-serm
GT201200074A (es) Combinación y composición que contiene un antimicrobiano, un glucocorticoide y un antimicótico
ECSP10010039A (es) Composiciones farmacéuticas liofilizadas
AR081882A1 (es) Forma cristalina de bencilbenceno inhibidor de sglt2

Legal Events

Date Code Title Description
FC Application refused